Mikhail Blagosklonny

Add links
Source: Wikipedia, the free encyclopedia.
Mikhail Blagosklonny
Alma mater
Anti-aging medicine, oncology
Institutions

Mikhail Blagosklonny is a scientist who studies

aging. He is an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York.[1]

Career

Blagosklonny earned both his

PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.[2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[1]

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of

rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.[5]

Editorial activities

Blagosklonny is

Cell Cycle,[7] and Oncotarget.[8] In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.[10]

The

predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[12] in July 2015.[11] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[13]

Health

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.[14]

References

  1. ^ a b "About Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. Retrieved May 14, 2021.
  2. doi:10.4161/cbt.8.9.8899
  3. doi:10.4161/cbt.8.9.8899
    .
  4. PMID 22279832
    .
  5. ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Bloomberg.com. 12 February 2015. Retrieved November 20, 2016.
  6. ^ "Editorial Board". Aging. Archived from the original on 2009-01-25. Retrieved 2016-11-20.
  7. ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
  8. ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  9. ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  10. ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
  11. ^ a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  12. ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  13. ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.
  14. ^ "My battle with cancer". 26 October 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mikhail_Blagosklonny&oldid=1197433230"